Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation

Launched by NOVARTIS PHARMACEUTICALS · May 30, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how the symptoms of Hidradenitis Suppurativa (HS) change over a year after starting a treatment called secukinumab. HS is a skin condition that can cause painful lumps and sores, and this study aims to understand how patients feel about their pain, any oozing from sores, and any unpleasant smells associated with the condition after they begin treatment.

To participate, you need to be at least 18 years old and have a confirmed diagnosis of HS. You also need to be starting secukinumab treatment as decided by your doctor, regardless of whether you choose to join the study. If you have any medical or psychological issues that might affect your ability to take part, or if you are already involved in another clinical trial, you won't be eligible. Participants will share their experiences and changes in symptoms over the 12 months following treatment, helping to provide valuable insights into managing HS.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male and female patients ≥ 18 years old,
• • 2. Patients who do not object to participation in the study,
• • 3. Diagnosis of HS clinically confirmed,
• • 4. Initiation of secukinumab treatment for HS in compliance with the summary of product characteristics,
• • 5. The physician's decision to initiate secukinumab has been taken according to his/her own practice and regardless of study participation.
• Exclusion Criteria:
• • 1. Patients with any medical or psychological condition which, in the physician's opinion, may prevent participation in the study,
• • 2. Patients participating in a clinical trial.

Trial Officials